Literature DB >> 25134970

Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry.

David R Barnidge1, Surendra Dasari, Marina Ramirez-Alvarado, Adrian Fontan, Maria A V Willrich, Renee C Tschumper, Diane F Jelinek, Melissa R Snyder, Angela Dispenzieri, Jerry A Katzmann, David L Murray.   

Abstract

We previously described a microLC-ESI-Q-TOF MS method for identifying monoclonal immunoglobulins in serum and then tracking them over time using their accurate molecular mass. Here we demonstrate how the same methodology can be used to identify and characterize polyclonal immunoglobulins in serum. We establish that two molecular mass distributions observed by microLC-ESI-Q-TOF MS are from polyclonal kappa and lambda light chains using a combination of theoretical molecular masses from gene sequence data and the analysis of commercially available purified polyclonal IgG kappa and IgG lambda from normal human serum. A linear regression comparison of kappa/lambda ratios for 74 serum samples (25 hypergammaglobulinemia, 24 hypogammaglobulinemia, 25 normal) determined by microflowLC-ESI-Q-TOF MS and immunonephelometry had a slope of 1.37 and a correlation coefficient of 0.639. In addition to providing kappa/lambda ratios, the same microLC-ESI-Q-TOF MS analysis can determine the molecular mass for oligoclonal light chains observed above the polyclonal background in patient samples. In 2 patients with immune disorders and hypergammaglobulinemia, we observed a skewed polyclonal molecular mass distribution which translated into biased kappa/lambda ratios. Mass spectrometry provides a rapid and simple way to combine the polyclonal kappa/lambda light chain abundance ratios with the identification of dominant monoclonal as well as oligoclonal light chain immunoglobulins. We anticipate that this approach to evaluating immunoglobulin light chains will lead to improved understanding of immune deficiencies, autoimmune diseases, and antibody responses.

Entities:  

Keywords:  Immunoglobulins; autoimmune diseases; kappa/lambda ratios; monoclonal; polyclonal

Mesh:

Substances:

Year:  2014        PMID: 25134970     DOI: 10.1021/pr5005967

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  8 in total

1.  Pseudo-monoclonal gammopathy: a report of four cases.

Authors:  Majd D Jawad; Ronald S Go; Thomas E Witzig; Joseph R Mikhael; Aishwarya Ravindran; David L Murrray
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

2.  Analysis of Monoclonal Antibodies in Human Serum as a Model for Clinical Monoclonal Gammopathy by Use of 21 Tesla FT-ICR Top-Down and Middle-Down MS/MS.

Authors:  Lidong He; Lissa C Anderson; David R Barnidge; David L Murray; Christopher L Hendrickson; Alan G Marshall
Journal:  J Am Soc Mass Spectrom       Date:  2017-02-28       Impact factor: 3.109

Review 3.  Bringing mass spectrometry into the care of patients with multiple myeloma.

Authors:  David L Murray
Journal:  Int J Hematol       Date:  2022-04-26       Impact factor: 2.490

Review 4.  Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory.

Authors:  Paula M Ladwig; David R Barnidge; Maria A V Willrich
Journal:  Clin Vaccine Immunol       Date:  2017-05-05

5.  Human plasma IgG1 repertoires are simple, unique, and dynamic.

Authors:  Albert Bondt; Max Hoek; Sem Tamara; Bastiaan de Graaf; Weiwei Peng; Douwe Schulte; Danique M H van Rijswijck; Maurits A den Boer; Jean-François Greisch; Meri R J Varkila; Joost Snijder; Olaf L Cremer; Marc J M Bonten; Albert J R Heck
Journal:  Cell Syst       Date:  2021-09-17       Impact factor: 10.304

6.  Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin.

Authors:  B Singh; A Kanack; A Bayas; G George; M Y Abou-Ismail; M Kohlhagen; M Christ; M Naumann; K Moser; K Smock; A Grazioli; D Murray; A Padmanabhan
Journal:  medRxiv       Date:  2021-09-24

7.  Extending the capabilities of intact-mass analyses to monoclonal immunoglobulins of the E-isotype (IgE).

Authors:  Wenhua Yang; Daniil G Ivanov; Igor A Kaltashov
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

8.  Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.

Authors:  David L Murray; Noemi Puig; Sigurdur Kristinsson; Saad Z Usmani; Angela Dispenzieri; Giada Bianchi; Shaji Kumar; Wee Joo Chng; Roman Hajek; Bruno Paiva; Anders Waage; S Vincent Rajkumar; Brian Durie
Journal:  Blood Cancer J       Date:  2021-02-01       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.